Amedeo Smart

Free Medical Literature Service


 

Amedeo

Vaccines

  Free Subscription

20.09.2021

1 Ann Intern Med
3 Arch Virol
9 BMJ
1 Clin Infect Dis
1 J Gen Virol
2 J Infect Dis
1 J Virol
2 JAMA
1 Lancet
3 MMWR Morb Mortal Wkly Rep
15 N Engl J Med
3 Nat Med
1 Pediatr Infect Dis J
1 PLoS Comput Biol
1 PLoS Med
5 PLoS One
1 Science
15 Vaccine



    Ann Intern Med

  1. AL-SAMKARI H, Leaf RK, Goodarzi K
    Transient Thrombocytopenia With Glycoprotein-Specific Platelet Autoantibodies After Ad26.COV2.S Vaccination: A Case Report.
    Ann Intern Med. 2021 Sep 14. doi: 10.7326/L21-0427.
    >> Share


    Arch Virol

  2. TANG P, Cui E, Song Y, Yan R, et al
    Porcine deltacoronavirus and its prevalence in China: a review of epidemiology, evolution, and vaccine development.
    Arch Virol. 2021 Sep 15. pii: 10.1007/s00705-021-05226.
    >> Share

  3. KIM SC, Jeong CG, Park GS, Park JY, et al
    Temporal lineage dynamics of the ORF5 gene of porcine reproductive and respiratory syndrome virus in Korea in 2014-2019.
    Arch Virol. 2021;166:2803-2815.
    >> Share

  4. FAWZY M, Khairy GM, Hesham A, Rabaan AA, et al
    Nanoparticles as a novel and promising antiviral platform in veterinary medicine.
    Arch Virol. 2021;166:2673-2682.
    >> Share


    BMJ

  5. PAGEL C
    Schools: a gaping hole in England's covid strategy.
    BMJ. 2021;374:n2115.
    >> Share

  6. DE BEER PAM, Van den Abbeele K
    Inviting adolescents aged 12-17 for covid-19 vaccination: the need for patience.
    BMJ. 2021;374:n2172.
    >> Share

  7. RIMMER A
    Covid-19: Government considers mandatory vaccination for healthcare staff in England.
    BMJ. 2021;374:n2222.
    >> Share

  8. CHRISTIE B
    Covid-19: Vaccine passports approved in Scotland despite criticism.
    BMJ. 2021;374:n2229.
    >> Share

  9. IACOBUCCI G
    Covid-19: Children aged 12-15 should be offered vaccine, say UK's chief medical officers.
    BMJ. 2021;374:n2248.
    >> Share

  10. DYER O
    Covid-19: US imposes mandatory vaccination on two thirds of workforce.
    BMJ. 2021;374:n2238.
    >> Share

  11. BLOCK J
    Vaccinating people who have had covid-19: why doesn't natural immunity count in the US?
    BMJ. 2021;374:n2101.
    >> Share

  12. IACOBUCCI G
    Covid-19: Vaccinating children will help end pandemic, says minister.
    BMJ. 2021;374:n2254.
    >> Share

  13. MUNRO C
    Covid-19: Boys are more at risk of myocarditis after vaccination than of hospital admission for covid.
    BMJ. 2021;374:n2251.
    >> Share


    Clin Infect Dis

  14. OHM M, Hahne SJM, van der Ende A, Sanders EAM, et al
    Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study.
    Clin Infect Dis. 2021 Sep 15. pii: 6370762. doi: 10.1093.
    >> Share


    J Gen Virol

  15. SIQUEIRA FERREIRA JM, Abrahao JS, Drumond BP, Oliveira FM, et al
    Corrigendum: Vaccinia virus: shedding and horizontal transmission in a murine model.
    J Gen Virol. 2021;102.
    >> Share


    J Infect Dis

  16. VAN PRAET JT, Vandecasteele S, De Roo A, Vynck M, et al
    Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents.
    J Infect Dis. 2021 Sep 13. pii: 6369254. doi: 10.1093.
    >> Share

  17. ZEEVAT F, Luttjeboer J, Paulissen JHJ, van der Schans J, et al
    Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom.
    J Infect Dis. 2021 Sep 15. pii: 6370470. doi: 10.1093.
    >> Share


    J Virol

  18. TOSTANOSKI LH, Gralinski LE, Martinez DR, Schaefer A, et al
    Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2.
    J Virol. 2021 Sep 15:JVI0097421. doi: 10.1128/JVI.00974.
    >> Share


    JAMA

  19. ABBASI J
    SARS-CoV-2 Variant Antibodies Wane 6 Months After Vaccination.
    JAMA. 2021;326:901.
    >> Share

  20. KUEHN BM
    Adolescent Myocarditis After COVID-19 Vaccination Is Rare.
    JAMA. 2021;326:902.
    >> Share


    Lancet

  21. PRIESEMANN V, Balling R, Bauer S, Beutels P, et al
    Towards a European strategy to address the COVID-19 pandemic.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01808.
    >> Share


    MMWR Morb Mortal Wkly Rep

  22. DELAHOY MJ, Ujamaa D, Whitaker M, O'Halloran A, et al
    Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021.
    MMWR Morb Mortal Wkly Rep. 2021;70:1255-1260.
    >> Share

  23. SIEGEL DA, Reses HE, Cool AJ, Shapiro CN, et al
    Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0-17 Years - United States, August 2020-August 2021.
    MMWR Morb Mortal Wkly Rep. 2021;70:1249-1254.
    >> Share

  24. REBMANN T, Loux TM, Arnold LD, Charney R, et al
    SARS-CoV-2 Transmission to Masked and Unmasked Close Contacts of University Students with COVID-19 - St. Louis, Missouri, January-May 2021.
    MMWR Morb Mortal Wkly Rep. 2021;70:1245-1248.
    >> Share


    N Engl J Med

  25. RAPEPORT G, Smith E, Gilbert A, Catchpole A, et al
    SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic.
    N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMp2106970.
    >> Share

  26. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Round of Rising Covid-19 Numbers.
    N Engl J Med. 2021;385:e41.
    >> Share

  27. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
    Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMoa2114255.
    >> Share

  28. FALSEY AR, Frenck RW Jr, Walsh EE, Kitchin N, et al
    SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMc2113468.
    >> Share

  29. THOMAS SJ, Moreira ED Jr, Kitchin N, Absalon J, et al
    Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMoa2110345.
    >> Share

  30. OKHOTIN A
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385.
    >> Share

  31. CHI H, Chiu NC, Lin CY
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385.
    >> Share

  32. ONISHI FJ, Goto JM
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
    N Engl J Med. 2021;385.
    >> Share

  33. JARA A, Undurraga EA, Araos R
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine. Reply.
    N Engl J Med. 2021;385.
    >> Share

  34. SALIH F, Schonborn L, Kohler S, Franke C, et al
    Vaccine-Induced Thrombocytopenia with Severe Headache.
    N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMc2112974.
    >> Share

  35. LIN CH
    BNT162b2 Covid-19 Vaccine in Adolescents.
    N Engl J Med. 2021;385.
    >> Share

  36. FRENCK RW JR, Dormitzer PR, Gurtman A
    BNT162b2 Covid-19 Vaccine in Adolescents. Reply.
    N Engl J Med. 2021;385.
    >> Share

  37. PATEL PD, Patel P, Liang Y, Meiring JE, et al
    Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
    N Engl J Med. 2021;385:1104-1115.
    >> Share

  38. TEBAS P, Roberts CC, Muthumani K, Reuschel EL, et al
    Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine.
    N Engl J Med. 2021;385:e35.
    >> Share

  39. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
    N Engl J Med. 2021;385:e48.
    >> Share


    Nat Med

  40. KOUP RA, Donis RO, Gilbert PB, Li AW, et al
    A government-led effort to identify correlates of protection for COVID-19 vaccines.
    Nat Med. 2021;27:1493-1494.
    >> Share

  41. ONEKO M, Steinhardt LC, Yego R, Wiegand RE, et al
    Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.
    Nat Med. 2021;27:1636-1645.
    >> Share

  42. APOSTOLIDIS SA, Kakara M, Painter MM, Goel RR, et al
    Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
    Nat Med. 2021 Sep 14. pii: 10.1038/s41591-021-01507.
    >> Share


    Pediatr Infect Dis J

  43. SENDERS S, Klein NP, Lamberth E, Thompson A, et al
    Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.
    Pediatr Infect Dis J. 2021;40:944-951.
    >> Share


    PLoS Comput Biol

  44. GOZZI N, Bajardi P, Perra N
    The importance of non-pharmaceutical interventions during the COVID-19 vaccine rollout.
    PLoS Comput Biol. 2021;17:e1009346.
    >> Share


    PLoS Med

  45. FIGUEROA JP, Hotez PJ, Batista C, Ben Amor Y, et al
    Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed.
    PLoS Med. 2021;18:e1003772.
    >> Share


    PLoS One

  46. MENA G, Blanco B, Casas I, Huertas A, et al
    Attitudes of Spanish hospital staff towards COVID-19 vaccination and vaccination rates.
    PLoS One. 2021;16:e0257002.
    >> Share

  47. LIMOTHAI U, Tachaboon S, Dinhuzen J, Hunsawong T, et al
    Dengue pre-vaccination screening test evaluation for the use of dengue vaccine in an endemic area.
    PLoS One. 2021;16:e0257182.
    >> Share

  48. DERUELLE P, Couffignal C, Sibiude J, Vivanti AJ, et al
    Prenatal care providers' perceptions of the SARS-Cov-2 vaccine for themselves and for pregnant women.
    PLoS One. 2021;16:e0256080.
    >> Share

  49. MALIK A, Malik J, Ishaq U
    Acceptance of COVID-19 vaccine in Pakistan among health care workers.
    PLoS One. 2021;16:e0257237.
    >> Share

  50. PRAVEEN C, Bhatia SS, Alaniz RC, Droleskey RE, et al
    Assessment of microbiological correlates and immunostimulatory potential of electron beam inactivated metabolically active yet non culturable (MAyNC) Salmonella Typhimurium.
    PLoS One. 2021;16:e0243417.
    >> Share


    Science

  51. MATEUS J, Dan JM, Zhang Z, Rydyznski Moderbacher C, et al
    Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells.
    Science. 2021 Sep 14:eabj9853. doi: 10.1126/science.abj9853.
    >> Share


    Vaccine

  52. THOMPSON MG, Soto G, Perez A, Newes-Adeyim G, et al
    Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)00982.
    >> Share

  53. ZHOU Z, Zhang X, Li Q, Fu L, et al
    Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.
    Vaccine. 2021 Sep 3. pii: S0264-410X(21)01165.
    >> Share

  54. PALACHE A, Rockman S, Taylor B, Akcay M, et al
    Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01157.
    >> Share

  55. YOSHIKAWA T
    Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01169.
    >> Share

  56. PARADOWSKA-STANKIEWICZ I, Rumik A, Bogusz J, Zbrzezniak J, et al
    Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents.
    Vaccine. 2021 Sep 9. pii: S0264-410X(21)01167.
    >> Share

  57. XU X, Rodgers MD, Guo WG
    A hub-and-spoke design for ultra-cold COVID-19 vaccine distribution.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01117.
    >> Share

  58. SUZUKI H, Noguchi T, Ogawa K, Miyazato P, et al
    Fusion of parvovirus B19 receptor-binding domain and pneumococcal surface protein A induces protective immunity against parvovirus B19 and Streptococcus pneumoniae.
    Vaccine. 2021;39:5146-5152.
    >> Share

  59. HAUPT RE, Harberts EM, Kitz RJ, Strohmeier S, et al
    Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00847.
    >> Share

  60. VAN DONGEN JAP, Rouers EDM, Bonten MJM, Bruijning-Verhagen PCJ, et al
    Evaluation of non-specific effects of human rotavirus vaccination in medical risk infants.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01115.
    >> Share

  61. MOLL K, Wong HL, Fingar K, Ke Zhou C, et al
    Vaccine exposure during pregnancy among privately and publicly insured women in the United States, 2016-2018.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01151.
    >> Share

  62. KUNITOKI K, Funato M, Mitsunami M, Kinoshita T, et al
    Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01145.
    >> Share

  63. ALBANI VVL, Loria J, Massad E, Zubelli JP, et al
    The impact of COVID-19 vaccination delay: A data-driven modeling analysis for Chicago and New York City.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01158.
    >> Share

  64. ABREU E SILVA HB, Correa HP, Ribeiro IA, Nascimento VAM, et al
    Impact of six years of routine varicella vaccination on the disease-related hospitalizations at Minas Gerais, Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01009.
    >> Share

  65. PLATT HL, Cardona JF, Haranaka M, Schwartz HI, et al
    A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01097.
    >> Share

  66. FUJISAWA S, Murata S, Takehara M, Aoyama J, et al
    In vitro characterization of adipocyte plasma membrane-associated protein from poultry red mites, Dermanyssus gallinae, as a vaccine antigen for chickens.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)01166.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016